csonnier39

Q1 2022 Earning Call Audio & Transcription

Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Updated with Seeking Alpha transcript: Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2022 Earnings Conference Call May 11, 2022 8:30…

Q4 2021 Earning Call Audio & Transcription

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Allison Wey – SVP, IR and Corporate Communications Paul Edick – Chairman and CEO Steve Pieper – CFO Conference Call Participants Roanna Ruiz – SVB Leerink Vamil Divan – Mizuho Securities David Amsellem – Piper Sandler Operator Hello everyone….

Fireside Chat with Paul Edick – Xeris Biopharma – $XERS

Fireside chat with Paul Edick – CEO of Xeris Biopharma – $XERS

What Lies Ahead For Xeris Biopharma In 2022

Jan. 1 PDUFA for Recorlev, Merck collaboration, Levothyroxine Phase 1, EIH Phase 2, and growing sales for Gvoke and Keveyis; Xeris has great potential for 2022.

2021 Q3 Earnings Call Recording

Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Edit: Transcription has been updated using Seeking Alpha | Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2021 Earnings Conference Call November 10,…

September 2021 Corporate Presentation Preview

These slides were part of the H.C. Wainwright 23rd Annual Global Investment Conference presentation which appear to be pages from the upcoming September 2021 Corporate Presentation.

$XERS – Ideal time to jump in

Source: r/pennystocks • Posted by u/ValterUdarnik • Original Post May you all be greeted fellow pennystockerians, today I want to remind you about XERIS, a commercial-stage pharma company which specializes in ready-to-use, liquid-stable injectables. I will present you some general information first to grasp the potential and after that the financial situation. Feel free to skip the parts…

Xeris enters into $71M Olguo commercialization agreement with Tetris Pharma

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe Up to $71 million in time- and milestone-based payments, plus royalties on sales Agreement covers 32 countries First launch expected in Q4 2021 in UKJuly 19, 2021 08:00 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq:…